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Abstract
Cerenkov luminescence imaging (CLI) is a novel imaging modality to study charged
particles with optical methods by detecting the Cerenkov luminescence produced in
tissue. This paper first describes the physical processes that govern the production and
transport in tissue of Cerenkov luminescence. The detectors used for CLI and their most
relevant specifications to optimize the acquisition of the Cerenkov signal are then
presented, and CLI is compared with the other optical imaging modalities sharing the
same data acquisition and processing methods. Finally, the scientific work related to CLI
and the applications for which CLI has been proposed are reviewed. The paper ends
with some considerations about further perspectives for this novel imaging modality.
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Introduction
Cerenkov luminescence imaging (CLI) is an optical imaging modality to study charged
particles of sufficient energy through the Cerenkov light they produce in biological tissue
[1–3]. Cerenkov luminescence is emitted when a charged particle traverses a dielectric
medium with a velocity greater than the phase velocity of light in the medium. The light
is emitted on a cone around the particle direction, with a typical continuous spectrum
proportional to the inverse wavelength squared. The range and the relatives intensities of
the emitted wavelengths are limited by the material properties. In tissue, the emitted light
is then highly scattered and absorbed before reaching the surface, and the tissue optical
properties tend to favor the transmission of the red-infrared light, where the Cerenkov
emission is minimal. Due to the low light level, the detection of Cerenkov luminescence
typical requires the same type of imaging system of bioluminescence, that is a high sensi-
tivity charge coupled device (CCD) coupled to a focusing optics and placed in a light-tight
environment.
Even if CLI suffers of challenges such as the low light yield and the limited pene-
tration depth, it has been proposed for several applications both in the preclinical and
clinical fields. In fact, apart from these limitations, up to date CLI offers a valid tool to
image β− radioisotopes, which can not be imaged with positron emission tomography
(PET) and for which Bremsstrahlung imaging has not shown promising results yet [4, 5].
Bremsstrahlung imaging typically uses single-photon emission computed tomography
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(SPECT) equipment (i.e., a gamma camera) to detect the higher energy (compared to
Cerenkov radiation) and broad spectrum radiation emitted by decelerating charged parti-
cles. Several studies have been performed using 90Y, as it emits almost purely β− particles
which can not be imaged with PET. Although some of these studies have shown the poten-
tial of 90Y Bremsstrahlung imaging, for example for accurate dosimetry purposes [6], even
in whole-body imaging [7], others have highlighted the limitations and challenges of this
imaging modality [4, 5, 8]. In particular, the low count rate and the continuous spec-
trum of Bremsstrahlung radiation limit the sensitivity and the quantitative capabilities
of Bremsstrahlung SPECT imaging. This, combined with the low spatial resolution and
the high amount of scatter intrinsic in SPECT imaging, requires sophisticated correction
methods for accurate dosimetry of activity levels [9, 10]. All these challenges suggest why
Cerenkov radiation has been proposed as a possible alternative means to study isotopes
such as 90Y.
CLI also offers a tool to image nuclear medicine probes with optical methods, which
are much cheaper than conventional detectors for higher energy photons, and would
therefore allow a larger spread of the imaging of these radioisotopes. Nonetheless, many
radioisotopes are already approved for clinical use, thus allowing immediate translation
to human applications.
Although CLI has been originally proposed for functional imaging of β-emitting
radioisotopes [1–3, 11–13], other applications have later been suggested, such as
Cerenkov-based surface dosimetry in external beam radiotherapy [14, 15] or the use
in proton therapy for quality assurance and in vivo dosimetry [16]. In proton therapy,
the high inherent spatial resolution of CLI compared to PET has been used to monitor
the proton range by imaging the proton-induced positron distribution [17]. In external
therapy, CLI has been utilized also for patient positioning and movement tracking [18].
Other applications suggested so far are Cerenkov luminescence endoscopy [19, 20] and
Cerenkov luminescence guided tumor surgical resection [21]. The possibility of enhanc-
ing the Cerenkov signal by wavelength-shifting it to more penetrating longer wavelengths
has also been evaluated [22, 23]. Another solution to increase the optical signal has
been proposed in [24], by developing a hybrid light imaging technique that uses a liquid
scintillator to assist CLI.
The investigation of this new imaging modality has also led to the exploitation of the
Cerenkov light produced in media different than tissue in other biomedical contexts. One
example is the utilization of the prompt Cerenkov emission in crystals used in positron
emission tomography (PET), as a opposed to the delayed emission of scintillation light,
with the goal of improving the time of flight performances of the imaging system [25].
Another example is the use of the Cerenkov light generated in plastic optical fibers for
proton therapy dosimetry [26].
This review paper introduces the physical basis of the Cerenkov emission and then
focuses on the light generation in tissue by radioisotopes. Some potential sources of
spurious luminescence in tissue are also discussed. Then, the processes governing the
transport of the emitted Cerenkov light in biological tissue are presented, followed by a
brief description of the detector components of an optical imaging system and of their
most relevant features for CLI applications. CLI is then compared with the other optical
imaging modalities sharing the same data acquisition and elaboration techniques (biolu-
minescence and fluorescence imaging). Unless specified, all the educational figures shown
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in this paper were adapted from [27]. In the last part of this paper, the studies on CLI
published up to date are reviewed, and some comments on CLI further perspectives are
proposed, followed by a short conclusion.
Review
Cerenkov light production
Cerenkov radiation is prompt bluish-white light emitted when a charged particle passes in
a dielectricmediumwith a velocity greater than the phase velocity of light in thatmedium.
The charged particle induces polarization of the molecules in the medium, and radiation
is emitted upon relaxation of these molecules. L’Annunziata [28] reports that Cerenkov
radiation was first observed by M. Curie in 1910, but dedicated experiments were not
performed until the 1930s, and in 1958 resulted in the award of the Nobel Prize to the
three main investigators, P. Cerenkov, I. Frank, and I. Tamm. A detailed description can
be found in [29], while more recent references are [30] or [31].
Cerenkov relation
The Cerenkov radiation is emitted on a cone around the particle direction. The charac-
teristic emission angle θ depends on the velocity of the charge β = v/c (with c being the
speed of light in vacuum) and the refractive index of the medium n, through the Cerenkov
relation (Fig. 1, left):
cos θ = 1
βn (1)
Therefore the Cerenkov angle is reduced as the particle slows down in the medium, as
shown in Fig. 1 (right) for different values of the refractive index, typical of air (n = 1.05),
water (n = 1.33), tissue (n = 1.4) and glass (n = 1.5). The Cerenkov relation (1) has three
consequences, due to the fact that β and cos θ are comprised between 0 and 1:




• minimum emission velocity: βmin(θ = 0) = 1n (Cerenkov threshold)
• limit on refractive index: nmin(θ = 0) = 1β
Fig. 1 Left: Pictorial description of the Cerenkov emission. Right: Cerenkov angle as a function of the particle
velocity, for different values of refractive index
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The Cerenkov threshold can be expressed in terms of the kinetic energy of the charged
particle with the following equation (using E = T + m0c2 = γm0c2):
Tmin = m0c2 [γ (βmin) − 1] (2)
wherem0c2 is the particle rest mass, γ =
√
1
1−β2 and E is the total energy of the particle.
For water (n  1.33 in the visible range) and for average soft tissue (n  1.4) the Cerenkov
threshold for a β particle is 264 and 219 keV, respectively. The threshold kinetic energy
for the Cerenkov emission by a β particle with rest mass m0c2 = 0.511 MeV is shown
in Fig. 2 (left) as a function of the refractive index of the medium, showing that in media
with a higher refractive index the Cerenkov threshold is lower, as suggested first in [32].
Due the dispersion of the refractive index as a function of wavelength (dN/dλ), different
wavelengths will have a slightly different Cerenkov threshold. For water, the variation of
the refractive index over the visible wavelength range (λ = 400 − 700 nm) is less than
7%, giving a variation of the Cerenkov threshold of less than 3%. The dispersion, together
with the energy loss and the multiple scattering of the charged particle in the medium,
causes a spread of the spatial distribution of the emitted light around the Cerenkov angle
and a finite duration of the light flash. However, these effects are not relevant for CLI
applications because the emission of the primary charged particles is itself continuous in
time and isotropic in space.
Cerenkov emission spectrum
The Cerenkov emission spectrum is peaked in the ultraviolet-blue and follows the one
over wavelength squared dependence by the Frank and Tamm formula. The number of











where α  1/137 is the fine structure constant. In terms of number of photons emitted
per unit path length and per unit wavelength, (3) becomes
dN







An example is shown in Fig. 2 (right) for an electron with β = 0.9 and n = 1.4,
constant for all wavelengths. Due to the non-linear relationship between energy and
Fig. 2 Left: Cerenkov threshold as a function of the refractive index of the radiator for a β particle
(m0c2 = 0.511 MeV). Right: Number of Cerenkov photons emitted per unit path length and per unit
wavelength by a particle with charge e and β = 0.9 in a medium with n(λ) = 1.4
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wavelength (E = 2πhc/λ), the energy spectrum of the emitted radiation appears
flat:
dN








The formula for the Cerenkov spectrum gives an infinite light production. In reality, it
has two cut-offs, at long wavelengths due to the medium self-absorption and at short
wavelengths in the X-ray region, where n becomes less than unity (in the so-called region
of anomalous dispersion) and the Cerenkov relation (1) is no longer satisfied [29].
As an example, Table 1 summarizes some figures of merit of the Cerenkov emission in
water and tissue. The Table reports the average refractive index of the twomaterials in the
(400–1000) nm range, the maximum angle of Cerenkov emission, the energy threshold
for Cerenkov production and the number of photons per mm produced in the (400–
1000) nm range. Due to the higher refractive index, the Cerenkov threshold in tissue is
lower than in water, thus the number of photons produced per unit path length is higher.
For water, more examples can be found in [33], which reports some calculated total num-
ber of Cerenkov photons produced in the range 250–600 nm in water by electrons of
different energies.
Comparisonwith other forms of energy loss
Energy loss for ionization To have an idea of the weakness of the Cerenkov radiation, it
is useful to note that for a minimum ionizing particle the rate of energy loss per unit path
length (dE/dx) due to Cerenkov emission is about 0.1% of that due to ionization [34]. In
terms of number of photons per unit path length (dN/dx), in [30], it is estimated that the
light output of Cerenkov emission is approximately two orders of magnitude weaker than
that of a plastic scintillator.
Bremsstrahlung radiation The Cerenkov effect should not be confused with
Bremsstrahlung radiative emission. The Cerenkov emission depends on macroscopic
properties of the medium through the index of refraction, while Bremsstrahlung emis-
sion is the result of an interaction of the moving charged particle with the Coulomb field
of the nucleus of the medium. If the charge travels close to the nucleus, it is slowed down
and emits radiation. The energy of this radiation is comparable to that of the moving
charge, and therefore much higher than that of the Cerenkov radiation. Jelley [29] esti-
mates that, for an electron traversing 1 cm of water with a kinetic energy of 100 MeV,
the ratio between the Bremsstrahlung signal and the Cerenkov signal in the visible range
λ = 400 − 500 nm is of the order of 10−5.
Table 1 Some figures of merit of the Cerenkov emission in water and soft tissue
Water Tissue
n, average in (400–1000) nm 1.33 1.4
θmax(β → 1) 41° 44°
Tmin(θ = 0), β particle 264 keV 219 keV
dN
dl (400 − 1000 nm), β → 1 20 ph/mm 23 ph/mm
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Cerenkov luminescence production in biological tissue
A significant fraction of the β particles emitted by radionuclides commonly used in
biomedical imaging have an energy above the Cerenkov threshold in tissue (Table 1), and
therefore are able to produce a detectable amount of Cerenkov radiation. Table 2 sum-
marizes some useful information for a few common radionuclides: the type of decay, the
half life, the endpoint energy and the fraction of β-particles above the Cerenkov threshold
in water (assuming n = 1.33) and tissue (n = 1.4). The endpoint energy determines the
fraction of β particles that are able to produce Cerenkov radiation. 18F-FDG (Fluorine-18
fludeoxyglucose or fluorodeoxyglucose) is used as a non-specific tracer to measure glu-
cose metabolism (mainly for oncological studies), Iodine-131 (131I) is a radiotherapeutic
used in nuclear medicine to treat thyroids affected by various diseases, while Yttrium-90
(90Y) is widely used in the radiation therapy of cancer (mainly in the liver), but also to
treat joints affected by rheumatoid arthritis. The study described in [35] surveyed several
radionuclides to characterize their Cerenkov light emission, showing in particular that
131I produces the smallest signal among the radioisotopes listed so far, followed by 18F
and 90Y, as indicated in Table 2.
Cerenkov luminescence production in biological tissue is a complicated process, result-
ing from several types of interaction. Let us take for example the simplified decay scheme
of 131I, and in particular let us consider the most probable decay. The 131I decay produces
an electron (with maximum energy of 606 keV) and one 363 keV γ photon. As summa-
rized in Fig. 3, Cerenkov radiation can be produced directly by the primary β particles (1)
or by secondary electrons with kinetic energy above the Cerenkov threshold. These sec-
ondary electrons can be δ rays produced by the primary β particles (2), photoelectrons or
Compton electrons produced by the γ ray (3) or by Bremsstrahlung radiation (4). Similar
considerations apply also to 18F, for which the contributions due to the two annihilation
photons should also be accounted for, while the process is much simpler for 90Y, as it
almost a pure β− emitter. In applications like proton-therapy, the scheme can be even
more complex, as described in [16]. However, when using biomedical radioisotopes, most
of the high energy photons interactions are Compton events, thus the energy transferred
to the electron is most often below the Cerenkov threshold. To confirm this, Monte Carlo
simulations performed by [36] have shown that the main contribution comes from the
primary β-particles, that emit the Cerenkov radiation very close to the point where the
radioisotope decays.
Figure 4 shows the distribution of the Cerenkov light production around a point source,
simulated with Geant4, for 18F (left) and 90Y (right), in water (n = 1.33, solid line) and
in tissue (n = 1.4, dotted line). The distributions were obtained considering in the sim-
ulations all contributions (1–4) in Fig. 3. For both radioisotopes, the spread of the light
Table 2 Characteristics of some radioisotopes
Isotope (decay) t1/2 Endpoint energy (keV)
Fraction above CT (%)
water tissue
(n = 1.33) (n = 1.4)
18F (β+) 109.8 min 633 42 58
90Y (β−) 64.1 h 2280 90 93
131I (β−) 8.02 days 606 25 37
CT = Cerenkov threshold
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Fig. 3 Pictorial description of the different processes that can lead to Cerenkov emission. Abbreviations:
Brems = Bremsstrahlung, photoel = photoelectron, δ = δ ray, C˘ = Cerenkov radiation. Adapted from [69]
production increases from water to tissue due to the reduction in the Cerenkov thresh-
old as a consequence of the increased refractive index (from approximately 264 keV to
219 keV, see Table 1). The different x and y scales for the two radioisotopes emphasize
two opposing aspects. Due to its lower energy, the 18F production is more limited in space
but also smaller in intensity. On the other side, 90Y has a worse spatial resolution since its
light distribution is broader (the electrons emitted by 90Y travel more than the positrons
of 18F before losing energy to the point of being below the Cerenkov threshold), but it can
be detected better due to the stronger signal.
For all radioisotopes, the Cerenkov emission by the primary β particles only is confined
within a few millimeters around the radionuclide position. This can be seen clearly in the
simulated results of Fig. 5 by [32]. The left part of the figure shows some β-particle tracks
emanated from a point source of 18F (top) and 90Y (bottom) in water, and the change
Fig. 4 Cerenkov emission range, defining the CLI intrinsic limit to the spatial correlation between the source
position and the position of production of the Cerenkov radiation, much like the positron range for positron
emission tomography. Simulated results were obtained including all the contributions to Cerenkov light
production (1–4) of Fig. 3
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Fig. 5 Left: Cerenkov production range simulated by [32], considering only the contribution of the primary β
particles (1) in Fig. 3. Right: simulated spread in the Cerenkov light production as a function of the β-particle
endpoint energy, for a few radionuclides (both with permission by [32])
in color indicates the point where the energy of the particles goes below the Cerenkov
threshold. The right part of the figure shows the root mean square spread of the Cerenkov
light production for a few radioisotopes, plotted as a function of the endpoint energy of
the β-particle.
The additional contribution from secondary particles (see Fig. 3) degrades the corre-
lation between the source position and the Cerenkov emission, producing light farther
away from the source, but this contribution is relevant only for high energy PET radioiso-
topes such as 89Zr [36]. It should be noted that the intrinsic limit to the spatial correlation
of the Cerenkov light production with the source position is smaller for CLI than for PET,
where it is determined by the positron range. However, in a real measurement this advan-
tage is negligible because the width of the spatial distribution of the detectable light is
largely dominated by scattering in tissue.
From what said so far about the phenomenon of Cerenkov production in tissue by β
particles, it is evident that the detectable signal in a CLI experiment depends on several
factors. Not only the refractive index determines the intensity of the light production,
but also the radioisotope being imaged (determining the fraction of β particles above the
Cerenkov threshold), and the density and geometry of the medium where the radioiso-
tope is located (determining the distance over which the β particles reach the Cerenkov
threshold due to their energy loss and the fraction of β particles that escape the vol-
ume before having lost enough energy to be below the Cerenkov threshold). We now
briefly present some sources of luminescence thatmight contribute to the reduction of the
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signal-to-noise ratio by increasing the background luminescent noise, and we will discuss
next how the transport in tissue also affects the final detectable Cerenkov signal.
Potential sources of spurious luminescence in tissue
Bremsstrahlung As previously discussed, the contribution of Bremsstrahlung emission
in the visible wavelength range is quite small. In addition, the probability of significant
Bremsstrahlung radiation production in tissue is low due to the low atomic number [1].
Autofluorescence and radioluminescence The tissue itself also plays the role of a con-
trast agent by naturally emitting luminescence upon external excitation. Autofluorescence
is the absorption and re-emission of light of longer wavelength due to small amounts of
fluorophores inherently contained in biological tissues [37]. This type of luminescence
can be either an unwanted background [38] or be intentionally exploited for imaging
purposes to distinguish normal from cancerous cells [39]. The relevance of the autofluo-
rescence induced by Cerenkov emission has not been investigated yet, but [38] assumes
that its contribution should be negligible for CLI. Radioluminescence is light production
in a material by bombardment with ionizing radiation and the role of radioluminescence
in tissue as a source of noise for CLI has not been investigated yet. 1
Black body radiation Another potential problem when performing optical imaging
could be the overlap with the black body emission in the infrared (IR), also called ther-
mal radiation. However, Wien’s displacement law predicts the maximum emission at
λ = 2.9/T · 106 nm · K, which for a body temperature of T  310 K corresponds to
approximately 9350 nm, far away from the Cerenkov emission range. Yet it should be
noted that black body radiation is successfully used for thermal imaging using infrared
cameras.
Cerenkov light transport in tissue
After being produced in biological tissue, Cerenkov radiation undergoes several interac-
tions before escaping the tissue and eventually reaching the detector. Proper modeling
of these interactions is essential for an accurate quantitative determination of the activ-
ity level responsible of the Cerenkov emission. The optical properties of the tissue
components that determine the propagation of light are the scattering and absorption
coefficients and the tissue inhomogeneity in the refractive index, which causes reflection
and refraction of the light. Most biological tissues are characterized by strong optical scat-
tering and weak absorption [40] and are therefore considered diffusive. These interactions
are the biggest challenge in any optical imaging modality, because they severely limit both
the spatial resolution (mainly due to scattering and discontinuity of the refractive index)
and the sensitivity (due to absorption). Refraction at the interface between tissue and air
may also impact the total number of detected photons. This is particularly crucial for CLI,
where the signal is already weak at production and the emission is on a broad spectrum,
over which the optical properties vary much.
Different studies have been performed to determine the optical properties of the var-
ious biological tissues (see for example [41] or [42]), but available data over the whole
visible spectrum are rather limited due to the strong dependence on the wavelength, the
tissue preparation and the measurement technique. Jacques [43] has provided empirical
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formulas to calculate the tissue optical properties for a given wavelength from factors
such as the content of water, fat and hemoglobin. However, the high variations in the
experimental data of different groups and studies seriously complicate the modeling of
the optical transport.
Based on [42], the light behavior in tissue can be summarized with the scheme shown
in Fig. 6. Light is strongly absorbed in the ultraviolet (λ < 380 nm) and far infrared
(λ > 2000 nm) spectral regions. Short wavelength visible light penetrates as deep as
0.5–2.5 mm, with an e-fold decrease of intensity with penetration in tissue, due to the
combined effect of absorption and scattering. In the 600–1600 nm wavelength range,
scattering dominates over absorption, and light can penetrate up to 8–10 mm.
Absorption
The absorption coefficient μa defines the probability per unit path length of photon
absorption in a medium. Its reciprocal is called mean absorption length. In a pure
absorber (no scattering) of thickness xwith absorption coefficient μa, the attenuation of a
collimated beam of light with incident intensity I0 is described by the Lambert-Beer law:
I(x) = I0e−μax
The absorption coefficient μa of a tissue is the sum of the contributions from all






In biological tissue, optical absorption is due mainly to hemoglobin, melanin and
water. The absorption spectra of these tissue components are shown in Fig. 7 (left), and
they were obtained form different sources: the absorption coefficient of hemoglobin (in
both its oxygenated and deoxygenated forms) was tabulated by Prahl [44], using data
by Gratzer and Kollias; the absorption of water was measured by Hale and Querry in
1973 [45]; the data for melanin were tabulated by Lister et al., [46] using data by Chan.
et al., [47]. As shown in Fig. 7 (left), absorption is stronger for ultraviolet light than for
longer wavelengths. Minor contributions from other tissue components usually do not
Fig. 6 Summary of the behavior in tissue of optical radiation of different wavelength, from data in [42]. The
penetration depth is indicated as d
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Fig. 7 Left: Absorption spectra of tissue components. Data for both oxygenated and deoxygenated
hemoglobin were taken from [44], water data by [45] and melanin data by [46]. Right: Monte Carlo simulation
of the modification of the Cerenkov spectrum in 1 cm of a typical tissue-like pure absorber (dotted line), with
the original Cerenkov emission spectrum as a reference
perturb significantly the optical transport and therefore are not significant if one is inter-
ested only in understanding light penetration. Absorbed light is converted into heat or
luminescence, or it is consumed in photochemical reactions [40].
In CLI, absorption causes the loss of the peculiar spectral distribution of the Cerenkov
light (proportional to the inverse wavelength squared). To help visualize this effect, a
Monte Carlo simulation was performed in Geant4. Figure 7 (right) shows an example of
the effect on the Cerenkov spectrum of pure absorption after traversing 1 cm of biological
tissue (the optical properties of chicken breast measured by [48] were used for this exam-
ple), indicating a stronger absorption at short wavelengths, and an almost unchanged
shape of the spectrum at long wavelengths.
Scattering
Optical scattering originates from light interaction with biological structures of differ-
ent size (from a few tenths of nm to hundreds of μm) and shape. Photons are scattered
more strongly by structures whose size matches their wavelength and whose refractive
index mismatches that of the surrounding media [40]. Scattering can be elastic or inelas-
tic (Raman). In an elastic scattering event, the trajectory of the photon is deviated. In an
inelastic scattering event, also the wavelength of the photon is changed according to the
conservation of energy. Raman inelastic scattering is known to be weak compared to the
elastic component (the study in [49] reports as a typical value that only one in 108 photons
undergoes Raman scattering in tissue) and is therefore usually neglected when treating
tissue optics.
Scattering of Cerenkov light causes the loss of the peculiar angular distribution of
the photons (on a cone around the particle direction). Figure 8 (left) reports simula-
tion results to show the effect of pure scattering, using the optical properties of chicken
breast measured by [48]. The crosses (with the dotted line identifying the cone) are the
positions of the Cerenkov photons belonging to the same vertex after traversing 1 cm of
non-scattering material. The circles are instead the positions of these photons after inter-
acting in a pure scatterer: the peculiar angular distribution of the Cerenkov light is no
longer visible.
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Fig. 8 Left: Monte Carlo simulation of the effect of pure scattering on the transmitted light distribution:
positions of the Cerenkov photons belonging to the same vertex after traversing 1 cm of either a
non-scattering material (crosses, producing the Cerenkov cone indicated by the dashed circle) or a tissue-like
scattering material (circles). Right: Difference between the scattering and the reduced scattering coefficients
(with permission from www.omlc.org, accessed on 21/12/2016)
There are three parameters that describe the scattering phenomenon and that can be
measured experimentally.
Scattering coefficient The scattering coefficient μs defines the probability per unit path
length of photon scattering in a medium. Its reciprocal is called scattering mean free path.
Anisotropy parameter The anisotropy parameter g is defined as the average cosine of
the scattering angle θ :
g = 〈cos θ〉 =
∫ π
0
p(θ) · cos θ · 2π sin θdθ (6)
The parameter g varies between -1 and 1: g = 0 corresponds to isotropic scattering
(Rayleigh), g = 1 to total forward scattering and g = −1 to total backward scatter-
ing. For biological structures, the average anisotropy parameter is g  0.9, denoting a
high probability of the photon to be scattered in the forward direction in each scatter-
ing event. However, after multiple scattering events the propagation direction is gradually
randomized [50], which is the reason why the Rayleigh approximation holds (see below).
Reduced scattering coefficient For diffusive media like biological tissue (μs  μa), the
anisotropy parameter allows to define the reduced scattering coefficient μ′s as:
μ′s = μs(1 − g) (7)
The difference between the scattering coefficientμs and the reduced scattering coefficient
μ′s is illustrated in Fig. 8 (right). With the reduced scattering coefficient, a random walk
made by many small anisotropic steps can be described with less equivalent big steps
involving isotropic scattering. For example, for tissue with g = 0.9, we have μ′s = 0.1μs,
therefore the reduced mean free pathMFP′ = 1/μ′s is ten times longer than the mean free
path MFP = 1/μs. This is of course valid only for diffusive media, where there are many
scattering events before an absorption event.
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The reduced scattering coefficient is not only convenient to reduce the computational
cost when modeling tissue optics, but it is also easier than the scattering coefficient to
be determined experimentally. In fact, the scattering coefficient μs is usually measured
by a collimated transmission measurement Tc through a slab of tissue of thickness l, so
that μs = − logTc/l, and requires a very thin slab (of the order of the scattering mean
free path which is less than 100 μm) to avoid multiple scattering events [43]. The mea-
surement of the reduced scattering coefficient μ′s is instead performed by diffuse light
measurements using thicker tissue slabs, which are easier to obtain. The two coefficients
allow to determine experimentally the coefficient as g = 1− μ′s/μs, otherwise difficult to
measure directly.
The scattering properties vary strongly among different biological tissues, and they are
heavily dependent on the light wavelength and on the measurement conditions. There-
fore, a summary of the values of these parameters is not presented in this paper. However,
a detailed review and additional references can be found for example in [43].
Scattering of light by a spherical particle can be modeled exactly by the Mie theory,
which reduces to the Rayleigh theory for light interacting with particles whose size is
much smaller than the incoming wavelength. The following paragraph briefly describes
the Rayleigh approximation, which might be useful when modeling the forward problem
of the transport of Cerenkov light in tissue. The reader is invited to refer to the published
literature, such as [40, 42] for more details and for a description of the more general Mie
theory.
Rayleigh scattering The Rayleigh theory models the elastic scattering of a plane




)  1, where nrel = nsnb is the relative refractive index of the scattering particle




is the size-parameter, that depends
on the size of the scatterer a and on the wavelength λ of the incident light. For visible
and NIR light and for nrel  1.05 − 1.1 as in tissue, the Rayleigh limit corresponds to
a < (12 − 14) nm, and is strictly valid only for subcellular structures [42].
In a Rayleigh scattering interaction, only the direction of the incident wave is changed,
while its wavelength is left unchanged. For unpolarized incident light I0 of wavelength λ,
the distribution of the scattered light intensity is given by:
I(t, θ) =
(






where θ is the scattering angle, r is the distance from the scatterer, α is the polarizability
of the particle (see below) and nb is the refractive index of the background medium. This
strong wavelength dependence is responsible of the stronger scattering of blue light with
respect to red light. The polarizability of a sphere with radius a is given by α = n2rel−1n2rel+2a
3.
Reflection and refraction
When an optical photon finds a discontinuity of the refractive index (an optical inter-
face), it has a certain probability to be reflected back or to be transmitted (refracted).
These probabilities are calculated with the Fresnel equations and depend on the refrac-
tive indexes of the materials forming the interface and on the polarization of the incident
photon [51].
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The refractive index of tissue ranges between 1.35 and 1.7 (Table 3). For soft tissue, a
refractive index n = 1.4 is usually considered [52], but variations have been reported from
sample to sample, place to place and time to time [43].
Detectors for CLI
Cerenkov luminescence imaging is typically performed in a light-tight environment with
a system comprising a sensitive charge-coupled device (CCD) and a high aperture lens
to increase the light collection efficiency. The most used imaging systems belong to the
IVIS series [1–3, 11, 12, 22, 24, 32, 36, 53–58], but also custom-built systems have been
employed [13–15, 17, 18, 21, 23, 59–62]. While IVIS imaging systems have been utilized
mainly for in vitro and small animal imaging, custom systems have been built, featur-
ing either intensified CCD cameras (ICCD) or electron-multiplying ones (EMCCD), for
microscopic imaging, for phantom studies to test the feasibility of CLI applications and
also for a few clinical human studies. Apart from the IVIS series, there are other commer-
cially available optical imaging systems which could be adapted for CLI measurements. A
list of some fluorescence imaging systems can be found in [63].
Choice of the photodetector
To optimize the detection of Cerenkov light, long exposure times and a completely dark
environment are required. A photodetector for CLI should have high quantum efficiency
over the wavelength range transmitted by the tissue being imaged, high sensitivity and
low noise. Back-thinned back-illuminated CCD sensors are typically employed to increase
quantum efficiency, while to reduce dark noise the CCD sensor is usually cooled down to
temperatures as low as −90° C or even less.
In electron multiplying CCDs (EMCCDs, [64]), the electrical signal produced by the
light impinging on the CCD sensor is amplified prior to readout in a so-called multipli-
cation register [65]. The use of EMCCDs is suggested for low light levels and when short
exposure times are required (dynamic imaging). If the signal intensity is high enough (i.e.,
more than 10 photons per pixel) or if long exposure times can be used, a conventional
CCD provides the highest SNR.
Intensified CCD cameras (ICCD) instead increase sensitivity by means of an image
intensifier screen placed before the CCD sensor. The incoming light hists the photocath-
ode at the entrance surface of the screen, producing photoelectrons. These photoelec-
trons are then accelerated towards a micro-channel plate, where they are multiplied and
accelerated again towards a phosphor screen which converts them back to an optical sig-
nal that is focused onto the CCD sensor [66]. Like EMCCDs, ICCDs are more sensitive
than conventional CCD sensors for very low light levels.
Table 3 Average values of refractive index of some tissue components
Component Refractive index Reference
Melanin 1.6–1.7 [40]
Adipose tissue 1.45 [52]
Kidney 1.417 [52]
Liver 1.367 [52]
Average soft tissue 1.4 [40]
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Another aspect worth noting is the spectral composition of the Cerenkov signal.
Although the emission is peaked in the UV-blue range, this part of the spectrum is more
strongly attenuated as the source depth in tissue increases. Therefore, as suggested also
in [67], photodetectors should be optimized for UV-blue light for surface imaging, but
should be more sensitive to longer wavelengths for deeper sources. In this respect, in [68]
it was estimated that the number of detected Cerenkov photons could be increased by up
to 35% by choosing a CCD camera with quantum efficiency peaked in the NIR range.
Choice of the optics
Choosing the right lens for a specific application is usually a complicated task, because
there are several factors that play a role in determining the imaging settings (e.g., the focal
length, the aperture and the minimum working distance). Nonetheless, these factors are
cross-correlated and constrain each other (for example because a longer focal length typ-
ically determines a longer minimum focusing distance, which in turn limits the allowable
field of view).
In CLI the main goal is to maximize the amount of collected light, therefore low
f-number lenses (corresponding to high aperture values) tend to be preferred. The f-
number, usually denoted as f /#, is the ratio of the lens focal length to the diameter of its
entrance pupil, which in a lens mount can be adjusted with an integrated iris. Increasing
the f /# by a factor of
√
2 halves the area of the aperture, decreasing the light throughput
of the lens by a factor of 2.
However, the f-number alone is not enough for the lens selection, because also a large
diameter or a shorter distance (typically corresponding to a shorter focal length) increase
the light collection efficiency. Despite this, usually the specific imaging application deter-
mines the field of view (FOV) to be imaged, therefore this is the fixed parameter that
constrains the others. For a given size of the FOV, the light collection efficiency depends
only on the lens f-number and on the sensor area. In particular, this efficiency is inversely
proportional to the square of the f-number and depends linearly on the sensor area. Other
limiting factors which should be considered are the minimum focusing distance, which
poses a limit to the maximum allowable FOV, and the fact that small f-numbers imply
small depths of field. A typical lens for optical imaging has a focal length of 25 mm and
f-number f/0.95.
Finally, in the same way as quantum efficiency is crucial for the photodetector selec-
tion, also the wavelength-dependent transmission and the level of impurities (resulting in
background luminescent emission) of the optical components should be carefully chosen.
As an example, in [67] the use of fused silica rather than Schott-75 glass was suggested to
improve sensitivity. In addition, long-pass filters have been employed for deeply located
sources to suppress the contribution of short wavelength Cerenkov photons produced
superficially (farther away from the source).
Other detection systems for CLI
CCDs are integrating devices, meaning that the signal produced is a measure of the total
detected signal, integrated over a certain amount of time. One group has used a photo-
multiplier tube coupled to fiber optics for proton-therapy dosimetry [26], while in [69]
digital silicon photomultipliers (SiPM) have been proposed as an alternative technology
to CCDs. SiPMs are single photon sensitive devices, in the sense that they produce an
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output signal that allows to discriminate each detected photon. This behavior, opposite to
the integrating one of CCDs, might be exploited for a more quantitative measurement of
the number of detected photons, which in turn could be quantitatively correlated to the
source activity.
CLI and other optical imagingmodalities
Cerenkov luminescence imaging relies on optical imaging methods to study the same
radionuclides as used in PET and SPECT, inheriting from conventional optical imaging
(bioluminescence and fluorescence imaging) the detection system, the image processing
and reconstruction algorithms, as well as the challenges and limitations due to limited
penetration depth of visible light. For these reasons, it seems natural to compare CLI with
these two imaging modalities, highlighting the common features as well as the differences
between the techniques.
Fluorescence imaging Fluorescence imaging uses fluorescent chromophores that are
injected into the subject under study and activated with an external excitation [70]. Since
the lifetime of the excited state of the fluorescent molecules is short (of the order of the
nanosecond or less), the activation can be repeated enabling high count rates and sensi-
tivity. The light emitted by the contrast agent is shifted towards more penetrating longer
wavelengths and is imaged with an optical system. The need for an external excitation
light causes a noise floor of autofluorescence and backscattered excitation light that is
only partially rejected by filtering out unwanted wavelengths. Fluorescence imaging is
currently used in surgery to identify the tumor volume as an aid in its resection [71]. Up to
date, the only clinically approved fluorescent contrast agents are fluorescein, methylene
blue and indocianine green (ICG).
Bioluminescence imaging Bioluminescence is the process of photon emission upon
oxidation of luciferin by luciferase [39]. Therefore luciferin, if injected into the subjects,
acts as a biomarker of gene expression, in particular by tumor cells, allowing in vivo
tumor imaging. However, its applications are limited only to cells expressing luciferase.
Bioluminescence imaging employs a spontaneous and single emission process on a lim-
ited wavelength range (500–565 nm, [70]). Even if there is no spurious emission due to
an external excitation source as in fluorescence imaging, background autoluminescence
from the bulk of the animal may limit the ability to detect bioluminescent probes [72].
Comparisonwith CLI
The differences between these optical imaging modalities and CLI are summarized in
Fig. 9. Fluorescence imaging requires an external excitation light and often a fluorescence
agent is injected to enhance contrast (left). Bioluminescence relies on the injection of
luciferin and on the presence of cells expressing luciferase (center). The CLI signal is pro-
duced spontaneously by a β-emitter in a medium with refractive index greater than air,
such as tissue (right).
To try comparing quantitatively the detectable signal with these three techniques, the
typical small animal photon count rates reported in [70] are of the order of (1-3)·104 cps
for CLI, 103 − 105 cps for bioluminescence imaging, and greater than 108 cps for fluores-
cence imaging. This relative comparison is in agreement with the description by [38] for
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Fig. 9 Overview of optical imaging modalities: fluorescence imaging (left), bioluminescence imaging (center)
and Cerenkov luminescence imaging (right). This figure was conceived taking inspiration from both [70, 132]
CLI and the three clinically approved fluorescent probes, which reports that the typical
emitted photon fluxes in CLI are two orders of magnitude smaller than those produced by
ICG andmethylene blue, andmore than three orders of magnitude weaker than the inten-
sity of the emission of fluorescein. The effect of tissue attenuation (higher in the Cerenkov
emission range than in the range of emission of the fluorescent probes) causes an addi-
tional difference of one order of magnitude in the detectable signals when adding 1 mm
of scattering tissue. However, one aspect that is worth noting is that bioluminescence and
fluorescence imaging uses have so far been limited mostly to the preclinical field. This is
due not only to the limitations in depth-penetration of optical radiation, but also to tox-
icity issues and long washout periods of optical probes, which restrict the utilization in
human studies. On the other side, there are many clinically approved radioactive tracers
and pharmaceuticals, which could be readily imaged in the clinic with CLI [73].
Optical tomography
As for tomographic imaging, the goal is to reconstruct the interior distribution of photons
from measurements at the tissue surface, thus requiring models of the light transport for
quantitative image reconstruction [70]. The solution of the inverse problem usually relies
on the diffusion equation, an approximation of the radiative transfer theory for diffu-
sive media [40]. Typically, numerical algorithms such as a Monte Carlo or finite-element
methods (FEM) are employed to invert the diffusion equation [74]. A priori infor-
mation (surface topography and the optical properties) and regularization approaches
(mainly Tikhonovmethod [75]) are usually required to solve the ill-posed inverse problem
[70, 76]. CT andmagnetic resonance imaging (MRI) may provide anatomical information,
useful for the surface segmentation and for the source localization, but neither of them
gives contrast that is directly related to the tissue optical properties. The surface topog-
raphy can be obtained also with structured light irradiation at an oblique angle, with the
method explained in [74].
In fluorescence tomography the emission takes place at a specific known wavelength,
therefore the optical properties of the subject at that wavelength can be measured a pri-
ori or during the acquisition, as done for example in fluorescence molecular tomography
(FMT, [77]). The intensity of the source is proportional to the absorption coefficient of
the fluorophore (at least for low concentrations). This absorption coefficient is itself pro-
portional to the fluorophore concentration in the tissue, that is related to the biological
process of interest. In a similar way, bioluminescence tomography (BLT) detects emission
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on a limited wavelength range (500–565 nm), and the intensity of the bioluminescent
source is proportional to the activity of the biological process [70]. In Cerenkov lumines-
cence tomography (CLT), the emission is on a broader range and the correlation between
the Cerenkov light distribution and the biological process is neither direct nor linear,
because the Cerenkov emission depends on factors as the refractive index of the tissue,
the isotope and the source geometry.
Applications and state of the art
As discussed in the introduction, Cerenkov luminescence imaging is particularly promis-
ing to image β− emitters, which are widely used for example in internal radiotherapy
but are difficult to visualize with other methods, such as Bremsstrahlung imaging. In
addition, CLI is able to provide images in a fast, easy and cost-effective way com-
pared to other methods in nuclear medicine, PET of β+-emitters [78] and single photon
emission computed tomography (SPECT) of γ -emitters [79], and in this respect CLI
would allow a larger employment of nuclear medicine probes also in facilities that do
not have conventional tomographic systems available. Apart from these uses related to
tumor diagnosis and treatment by injection of radionuclides, encouraging applications
for CLI are endoscopic and intraoperative ones, as well as dosimetry in external beam
therapy.
In this part of the paper, we first describe which are the sources of Cerenkov lumines-
cence of biomedical interest, to underline the potential capabilities of CLI. We then give
an overview of the literature on this novel imaging modality, trying to cover all suggested
uses up to date.
Biomedical sources of Cerenkov luminescence
We have seen that Cerenkov luminescence can be produced by charged particles of suf-
ficient energy, and that for electrons and positrons the Cerenkov threshold in tissue is
approximately 220 keV. Therefore, in principle any β-emitting radioactive source pro-
ducing decay products with energy above this value can be imaged with CLI. However,
different radioisotopes will produce a signal of different intensity (producing between 1–
100 Cerenkov photons per decay [32]), and thus will have a different minimum detectable
activity level.
The PET radionuclide which has been mostly studied with CLI is certainly 18F, as it
is widely used in clinical practice. Other imaged tracers are for example 13N, 64Cu and
89Zr. As for β− emitters, images have been obtained of 131I, 90Y, and 32P, to name but
a few. A list of the β-emitting radioisotopes that have been studied with CLI up to date
is reported in Table 4 (decay mode branching ratios and endpoint energies were taken
from [80]). As summarized in [73], the number of Cerenkov photons per disintegra-
tion produced by some of the radionuclides in Table 4 is 64Cu > 18F > 89Zr > 124I >
68Ga > 90Y.
The potential to image γ emitters such as ∗99mTc with optical methods has also been
investigated [11, 35, 81–83]. However, the energy of the emitted γ (140.5 keV) is well
below the Cerenkov threshold. Therefore, it is reasonable to assume that the lumines-
cence observed experimentally (for example in [82]) is not due to Cerenkov effect but
rather to other physical processes resulting in luminescent emission (e.g., radiolumines-
cence), as suggested in [83, 84]. In addition, the luminescent emission spectrum of ∗99mTc
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Table 4 List of β-emitting radioisotopes studied with CLI up to date
Radioisotope Type of decay Endpoint (keV) References
18F β+ (97%) 633 [1–3, 11, 12, 32, 35, 36, 110, 115]
[22, 24, 58, 60, 116, 131, 133, 134]
13N β+ (100%) 1198 [1, 58]
64Cu β+ (18%) 653 [2, 11, 23, 35, 135]
68Ga β+ (88%) 1899 [36, 55]
89Zr β+ (23%) 2400 [2, 22, 36, 58, 109, 136]
124I β+ (12%) 1534 [2, 57, 113]
32P β− (100%) 1710 [54, 137]
90Y β− (99.9%) 2280 [32, 35, 56, 58, 133, 138]
111In AE after ECa (100%) 448 [35, 36]
131I β− (90%), γ (82%) 606, 364 [2, 24, 35, 59, 100, 114]
177Lu β− (78.6%) 498 [35, 56]
198Au β− (99%) 961 [107]
aAE is Auger electron emission after electron capture (EC)
has shown to be heavily material dependent, contrasting with the behavior of Cerenkov
light [85].
The applicability of CLI also to α-emitting radioisotopes has been investigated
[2, 86–88]. However, due to their large mass, the threshold kinetic for α-particles to pro-
duce Cerenkov radiation in tissue is higher than 1500 MeV, while the typically α-decay
energies are of the order of a few MeV [33, 87]. Also the energy transfered through elas-
tic scattering to the electrons released during tissue ionization is below the Cerenkov
threshold for β-particles, because these electrons can receive only a small fraction of the
α energy (4meMα/(M2α + m2e ), where me and Mα are the rest masses of the electron and
α, respectively [36]). For these reasons, the strong optical signal measured in [2, 86] has
so far been explained as the Cerenkov emission due to daughter nuclei. In addition, the
delay in time of this phenomenon decreases the correlation between the Cerenkov light
production with the radioisotope distribution [87], thus limiting the applicability of CLI
to α emitters.
The last category of biomedical particles which can be imaged with CLI are external
radiation beams [14, 15, 18, 89–91]. In fact, megavoltage photon beams, as well as elec-
tron and proton beams produced with energies of typical clinical applications (6-18 MeV,
[92]) can produce Cerenkov light by secondary electron emission. Monte Carlo simula-
tion results by [61] predict high Cerenkov light fluence rates from external radiotherapy
beams (300–500 nW cm-2 (Gy s-1)-1 including the effects of absorption by tissue).
Preclinical applications
The preclinical field is particularly suitable for CLI applications, because the reduced
dimensions of the animal allow the Cerenkov light to escape the tissue surface and to
be detected. Many uses have been tested, and an overview of the related references is
presented here.
Oncological uses Preclinical CLI can be used for example to monitor tumor therapy
[93, 94] and to monitor radiotherapy with radiolabeled peptides [95]. In the study by [93]
(Fig. 10a), the tumor staging was monitored over time in a mice vehicle group and in a
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Fig. 10 Examples of preclinical CLI and CLT. a Tumor treatment monitoring over time in a vehicle group and
in a group treated with an anti-tumor agent [93] (with permission). b Reconstruction of the activity
distribution with Cerenkov luminescence tomography (green, top) and with PET (red, bottom) as done by [96]
(with permission). c Reconstructed msCLT trans-axial slice co-registered with MRI from [54] (with permission).
The reconstructed slice position is highlighted in green in the bottom part of the figure
group having the same tumor treated with an anti-tumor agent: CLI data obtained with a
PET contrast agent showed the tumor growth over a month in the vehicle group (top row)
and its reduction in response to treatment in the other group (bottom row). In another
study [95], targeted peptides for the diagnosis and radiotherapy of gastric cancer were
radiolabeled with 131I and imaged with CLI to assess their tumor binding affinity and
antitumor efficacy.
Cerenkov luminescence tomography Due to the attenuation of Cerenkov light in tis-
sue, a tomographic acquisition is required to decouple the intensity of the radioactive
source from its position at depth in tissue [70]. A few groups have investigated the
capability to reconstruct the source position and distribution in tissue with Cerenkov
luminescence tomography (CLT). In particular, [96] has shown with phantom and in vivo
studies that the source distribution inside objects could be reconstructed from surface
measurements using the diffusion equation to model the optical transport and a precon-
ditioned conjugate gradient method to iteratively solve the inverse problem. Figure 10b
shows the result of the reconstruction in tissue (green) superimposed on the anatomi-
cal CT image, validated with the PET acquisition (red). The calibrated PET image also
allowed the activity quantification, which was not possible from the CLT images. The
acquisition was done filtering out short wavelengths to suppress the contribution of
Cerenkov photons emitted at the surface of the animal (presumably farther away from
the source), and assuming constant optical properties on the detected wavelength range
(695–770 nm). This allowed the inversion, but limiting the quality of the reconstruction.
A similar study was performed by [97], based on a heterogeneous mouse model rather
than on an homogeneous one and using SPECT instead of PET for validation. Also in this
case, a bandpass filter was used to collect only long wavelengths (675–775 nm). The prob-
lem was further investigated also in [13, 98, 99], and in [100] CLT was used to quantify
tumor association of a radiolabeled peptide.
A different approach was used by [54]. This group applied the multi spectral 3D image
reconstruction approach called diffuse luminescence imaging tomography [74] to obtain a
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3D image of the Cerenkov light distribution, and named this techniquemulti spectral dif-
fuse Cerenkov luminescence tomography (msCLT). As the name suggests, this approach
combines the information at different wavelengths obtained by images acquired using
a number of narrow bandpass filters. Therefore, this method relies on a set of 2D pla-
nar images acquired from the same point of view, rather than using multiple projections.
The result of the reconstruction is shown in Fig. 10c for a brain trans-axial slice. The
reconstructed Cerenkov light distribution is superimposed on the magnetic resonance
anatomical image for localization, and the slice shown is highlighted in green in the
bottom part of the figure.
Cerenkov luminescence for internal excitation Another interesting application is the
release at depth in tissue of excitation light to fluorophores or nanoparticles [11, 12,
101–105]. Applications falling in this category are often referred to as Cerenkov-excited
luminescence applications [92]. This type of use of Cerenkov light has the potential to
increase the light output in two ways: by overcoming the tissue penetration limit of exter-
nal excitation lamps required for fluorescence imaging, and by simultaneously shifting
the Cerenkov spectrum peak towards longer wavelengths (typically λ = 560 − 800 nm).
Wavelengths in the so-called near-infrared (NIR) window (also known as optical window
or therapeutic window, λ = 650 − 1350 nm) are in fact more penetrating (Fig. 6). To
this purpose, in [22] it has been shown that targeted and activatable fluorescent probes
excited by Cerenkov luminescence can be created (coupling 18F-FDG to quantum dots),
thus allowing to image two molecular information: metabolic activity through 18F-FDG
and integrin expression through the quantum dot excited by the 18F-FDG. In [106], it has
been shown that PET probes such as 18F-FDG can also be used as a source of light for
photoactivation of caged luciferin in a breast cancer animal model expressing luciferase.
In another study, radioluminescent Au nanocages were developed with the aid of CLI
visualization [107]. To enhance the CLI signal, in [11] PET tracers were coupled to quan-
tum dots to improve optical imaging in biological systems. Another group has suggested
using europium oxide nanoparticles excited by the Cerenkov luminescence produced by
radiopharmaceuticals to increase sensitivity in a tomographic setting [108].
Other preclinical CLI applications Potential uses of preclinical CLI which have been
evaluated are also intraoperative imaging of radionuclides [109], surgical resection [110],
endoscopic imaging for intraoperative surgical navigation [111], study of gene expression
[57, 112–114], dynamic imaging [115], interscapular brown adipose tissue visualization
[116], quantitive tissue oxygenation assessment [117], and negative contrast imaging of
blood vessel attenuation of Cerenkov light to image vasculature [55]. In [118], Cerenkov-
specific contrast agents for pH detection have been developed, while in [119] antibody-
based PET radiotracers have been evaluated via CLI.
External beam radiotherapy
Work has been done also to investigate CLI uses in external beam radiotherapy. The study
of [89] has shown that electron beams produce CL which can excite fluorescent agents
for dual therapy (from the external beam and from local phototherapy), and projection
imaging of photon beams using Cerenkov-excited fluorescence has been evaluated in [14].
CLI has been proposed also as a tool to monitor the efficacy of external beam radiother-
apy [15], suggesting time-gated acquisition to avoid the issues coming from unwanted
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ambient light [120]. The use of CLI has been proposed also for beam quality assurance
and for dose calibration [121, 122]. Two more recent studies showed how CLI can visu-
alize radiation therapy in real time during breast radiation therapy [91], and used beams
produced by medical linear accelerators to induce Cerenkov luminescence in tissue phan-
toms, naming this technique CELSI, for Cerenkov-excited luminescence scanned imaging
[62]. Another study used CLI for patient positioning and movement tracking [18]. The
use of the Cerenkov light generated in plastic optical fibers for proton [26] and photon
[123] therapy dosimetry has also been considered. Finally, simulation results have ana-
lyzed theoretically the physics of Cerenkov emission during proton therapy [16], and the
correlation between the captured Cerenkov light and the expected dose for x-ray photons,
electrons, and protons [122].
Quantitative CLI
Some groups have also investigated the quantitative capabilities of CLI. This was done for
example by correlating quantitatively the CLI signal with either the PET or SPECT signal
[94]. Other studies have shown that the CLI signal is linear with dose in external therapy
[15], or with activity in radiopharmaceutical imaging [124]. An example of the correlation
of the CLI signal with the PET signal (x-axis, expressed in mean percent injected activ-
ity per gram) is shown in Fig. 11 (top). The correlation between the two signals is high
(R2 = 0.98), and the fit equation y(x) calibrates the signal measured with CLI with that
Fig. 11 Examples of quantitative CLI. Top: Quantitative analysis of CLI and PET signals [2] (with permission).
Bottom left: Decay in time of the count rate due to 18F measured by the PDPC, before and after data
correction [27]. Bottom right: Linearity of the Cerenkov count rate in the PDPC with the 18F activity level,
adapted from [69]
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of PET. Since PET can be calibrated to quantify the functional information, by means of
this cross-calibration it is possible to relate the CLI measured quantity with the source
activity distribution, thus fulfilling both requirements of functional imaging (imaging and
quantification of the activity distribution). An overview of the published literature on the
correlation of CLI and PET can be found in [67].
One study has investigated the quantitative capabilities of digital silicon photomulti-
pliers (dSiPMs) for CLI [69]. In fact, dSiPMs provide directly the number of detected
photons and might therefore allow an easier quantitative reconstruction of the activ-
ity with respect to CCDs (which instead require some sort of calibration to recover
the number of detected photons). This preliminary feasibility study showed that, with
a sequential activation of the cells of the dSiPM and with proper data correction, the
detector responded dynamically to different activity levels and source depths in tissue. In
particular, the 18F half life could be obtained from the experimental data with very high
precision. Figure 11 (bottom left) shows the effect of the data correction algorithm on the
18F decay curve in time (from [27]), Figure 11 (bottom right) shows the linearity of the
Cerenkov count rate in the PDPCwith the 18F activity level, after data correction (adapted
from [69]).
Simulation studies
A few groups have compared CLI results with Monte Carlo simulations that predicted
the light production in different conditions. In fact, as we have seen the Cerenkov
light production depends on several factors. Therefore, it is not trivial to determine the
Cerenkov light distribution produced by a given activity distribution and the intensity of
the detectable signal in a certain experimental condition.
In particular, [32, 58] have developed a code to determine the Cerenkov light produc-
tion in water and tissue for many isotopes. The light yield predicted by their Monte Carlo
code in [58] is shown in Fig. 12 (left), plotted versus the light yield they measured exper-
imentally for some isotopes. As indicated in the graph axis, only a relative comparison
of the simulated and measured light yield could be done (both quantities are normal-
ized to the 18F light yield) due to a constant factor two-discrepancy between simulated
and experimental results reported by the authors. In [58], the group has also studied the
dependence of the Cerenkov light production on factors like the index of refraction and
the geometry of the experimental setup.
A similar study has been performed also by [36]. The results of this group have shown
to be consistent with those of [32] and a set of corrections of the simulated predictions to
match the experimental results have been proposed.
In [27, 125], analogous simulations in Geant4 have been performed and compared
with experimental measurements. In this case, a custom-built CCD-based imaging sys-
tem featuring an EMCCD was used rather than the IVIS. The geometrical light collection
efficiency of the lens was determined experimentally, and inserted in the Monte Carlo
simulation together with the information available on the detector spectral response.
This allowed an absolute quantitative comparison of the number of detected photons
predicted by the simulation and measured experimentally. Preliminary results using 18F
and 90Y in water solutions suggested that the Monte Carlo is able to predict the mea-
sured Cerenkov photon counts with only a 20% underestimation of the true values. As
shown in Fig. 12 (right) (adapted from [125]), this constant offset was reproducible among
Ciarrocchi and Belcari EJNMMI Physics  (2017) 4:14 Page 24 of 31
Fig. 12 Left: Relative comparison of measured and simulated Cerenkov light yield for a few radionuclides in
water [58] (with permission). Right: Simulated over measured Cerenkov count rate with different acquisition
settings (top) and as a function of activity, for two combinations of acquisition settings (bottom); both figures
were adapted from [125]
different acquisition settings (e.g., varying the pixel binning factor and exposure time, top)
and different activity levels (bottom), provided that the activity was above the minimum
radioisotope activity level that can be detected with CLI. Additional measurements with
tissue samples and emission filters to separate Cerenkov spectral components are being
carried out to confirm these preliminary results.
Other groups have done simulation studies with different goals. In particular, in [15]
CLI measurements have been compared withMonte Carlo predictions of superficial dose
distribution in external radio therapy, and a hybrid Monte Carlo tool has been developed
[126] that has been used for a breast study [127] and for small animal imaging [128].
Clinical applications
Clinical images of 131I-iodide metabolic radiotheraphy of a diseased thyroid (Fig. 13a,
[59]) and of 18F-FDG positive lymph nodes [60] have been acquired successfully. In the
clinical field, CLI could be advantageous also during endoscopy (by exploiting the natural
body cavities) and useful in intraoperative practice, to detect and highlight diseased tis-
sues and to guide surgical resection [19, 21, 109, 129]. The first clinical endoscopic CLI
imaging system has been developed for human studies, and preliminary images of dis-
eased and healthy tissue are shown in Fig. 13b by [20]. A successful resection of a sentinel
lymph node has been shown by [110], while in [130] ex vivo CLI of a human brain tumor
specimen removed during neurosurgery has been shown (Fig. 13c). A CLI intra-operative
imaging device has been developed by LightPoint Medical Inc., and the first clinical tri-
als are ongoing to demonstrate its utility to assess tumor margins during surgery [67]. As
for external beam radiotheraphy, an example of the real-time imaging of a breast treat-
ment is shown Fig. 13d by [91]: the beam’s eye view of the treatment is shown on the left,
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Fig. 13 Examples of clinical CLI. a First human CLI image of a thyroid suffering from hyperthyroidism treated
with 550 MBq of 131I-iodide, 24 h after administration [59] (with permission). b CLI endoscopy (ECLI) of
cancerous (left) and normal tissue (right), by [20] (with permission). c Ex-vivo CLI of human brain tumor
removed during neurosurgery, by [130] (with permission). d Real-time CLI of human breast external radiation
therapy, by [91] (with permission): beam’s eye view of treatment (left), corresponding skin projection (center)
and Cerenkov emission image (right)
together with the corresponding skin projection (center) and Cerenkov emission image
(right).
Further perspectives
One important aspect to be considered to fully exploit the potential of CLI as a stand-
alone imaging modality is to understand its quantitative capabilities. Taking for example
the functional imaging of a radioactive distribution, quantitative CLI means that the
measured quantity (a signal proportional to the Cerenkov radiance emitted at the tis-
sue surface) is quantitatively and spatially correlated to the activity distribution at depth
in tissue (as mentioned earlier, due to the attenuation of optical light in tissue, this can
potentially be achieved only with a tomographic acquisition).
In PET, the requirements of quantitative and spatial correlation of the measured sig-
nal to the activity distribution are fulfilled by combining the PET functional information
with the morphological information obtained with computed tomography (CT). The CT
measurement provides the source localization and the correction for the attenuation of
the detected PET signal. In addition, the quantitative information is obtained by calibrat-
ing the response of the PET imaging system with a reference standard, e.g., a phantom
uniformly filled with a radioactive solution.
With respect to PET, the reconstruction in CLT is complicated by the absence of a tissue
equivalent material able to mimic the tissue interactions with visible light over the entire
Cerenkov spectrum and by the lack of a reference standard (as is water for PET) to cali-
brate the detector response in terms of emitted radiance at the tissue surface. In addition,
the optical properties of the various tissues, that regulate the light transport between pro-
duction and emission at the tissue surface (equivalent to what in PET is corrected with
the CT attenuation correction), are often not known, and available data are restricted to
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a few wavelengths. Also with respect to conventional optical tomography (biolumines-
cence and fluorescence tomography), the broad-band nature of the Cerenkov emission
and the complex correlation between the distribution of the emitted Cerenkov light and
the activity distribution complicate the CLT reconstruction.
For all these reasons, up to date a complete quantitative reconstruction of the activity
distribution from a CLT acquisition has not been demonstrated, unless by means of a
cross-calibration with PET or SPECT (see for example [96]). In principle, for a tissue with
known optical properties, the inverse problem in CLT could be solved with the following
steps:
1. calibration of the response of the imaging system to obtain the surface radiance;
2. reconstruction of the Cerenkov light distribution at production at depth in tissue
from the surface radiance;
3. reconstruction of the isotope distribution from the Cerenkov light distribution;
4. localization of the activity distribution.
Supposing that the first two steps of this algorithm can be borrowed by conventional
optical tomography, that the optical properties of the tissue can be somewhat measured
and that anatomical information is available, one possible solution to correlate quantita-
tively the Cerenkov light production distribution to the radiotracer distribution is to use
Monte Carlo simulations to predict the Cerenkov light output of a given distribution, as
those in [27, 32, 36, 58]. However, the feasibility of this method in practice still needs to
be fully proven and would be a very interesting subject for future studies.
Conclusions
Cerenkov luminescence imaging (CLI) is a simple, fast and cost-effective tool to image
radioisotopes and particle beams. Yet, CLI suffers from all the drawbacks of optical
imaging (reduced penetration depth and complex transport in tissue), with additional
limitations due to the broader emission spectrum and to the non-linear correlation with
the distribution of the primary source responsible of the Cerenkov emission. However,
the potentialities of this technique in the preclinical, but also clinical field, justify a grow-
ing interest toward CLI. In fact, this imaging modality can be used to study radiotracers
and radiopharmaceuticals employed for oncological uses, also in endoscopic and intra-
operative contexts. It can be useful also for dosimetry and other purposes in photon,
electron and proton beam therapy. The Cerenkov signal can be enhanced if used to excite
fluorescent agents, having potential usability also for photoactivation and phototherapy.
Nevertheless, further research is needed in this field to move from a qualitative to a true
quantitative molecular imaging technique.
Endnote
1 It should be noted that recently a technique termed radioluminescence imaging
(RLI) has been explored [84, 131], but this method uses the luminescence produced by
radioactive sources in scintillating crystals rather than in tissue.
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